Oxurion Announces Preclinical Data on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Retrieved on:
Tuesday, May 3, 2022
Vance DeGeneres, Euronext, DME, Integrin, Research, ARVO, Patient, Fibrosis, Intravitreal injection, Association, Diabetic retinopathy, Retina, Inflammation, Macular edema, Allograft inflammatory factor 1, Diabetes, Association for Research in Vision and Ophthalmology, RATS, Central retinal vein occlusion, Annual general meeting, STZ, Pharmaceutical industry, Ophthalmology, Carlo Emilio Bonferroni
Preclinical data shows THR-687s potent inhibition of vascular permeability, inflammation and reactive gliosis in diabetic rats supporting evidence of clinical utility of THR-687 in multiple retinal diseases.
Key Points:
- Preclinical data shows THR-687s potent inhibition of vascular permeability, inflammation and reactive gliosis in diabetic rats supporting evidence of clinical utility of THR-687 in multiple retinal diseases.
- Targeting RGD-binding integrins is known to affect multiple disease hallmarks such as vascular leakage, inflammation, angiogenesis and fibrosis.
- The preclinical study investigated the therapeutic potential of THR-687, a potent pan-RGD integrin antagonist, in the streptozotocin (STZ)-induced diabetes rat model.
- This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction.